CIK 0001815776 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844867570
- Phone
- 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-11 | Stultz Katherine V CHIEF OPERATING OFFICER | Grant or award · Series B Preferred Stock | +19,763 | $5.06 | $100K | 19,763 |
| 2021-03-11 | JIMENEZ JOSEPH Director | Grant or award · Series B Preferred Stock | +19,763 | $5.06 | $100K | 19,763 |
| 2021-03-11 | KARSEN PERRY A Director | Grant or award · Series B Preferred Stock | +19,763 | $5.06 | $100K | 19,763 |
| 2021-03-11 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Grant or award · Series B Preferred Stock | +19,763 | $5.06 | $100K | 19,763 |
| 2021-03-11 | Jerel Davis Director | Grant or award · Series B Preferred Stock | +3,715,415 | $5.06 | $18.8M | 3,715,415 |
| 2021-02-16 | Jerel Davis Director | Grant or award · Series A Preferred Stock | +10,000,000 | $1.00 | $10.0M | 30,019,945 |
| 2021-01-16 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Option exercise | +374,013 | $0.30 | $112K | 1,153,544 |
| 2021-01-16 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Option exercise · Stock Option (right to buy) | −374,013 | 0 | ||
| 2021-01-15 | Gutry Phil CHIEF BUSINESS OFFICER | Option exercise | +91,406 | $0.30 | $27K | 281,962 |
| 2021-01-15 | Gutry Phil CHIEF BUSINESS OFFICER | Option exercise · Stock Option (right to buy) | −91,406 | 0 | ||
| 2021-01-14 | JIMENEZ JOSEPH Director | Option exercise | +49,876 | $0.30 | $15K | 153,815 |
| 2021-01-14 | JIMENEZ JOSEPH Director | Option exercise · Stock Option (right to buy) | −49,876 | 0 | ||
| 2021-01-13 | Gutry Phil CHIEF BUSINESS OFFICER | Grant or award · Stock Option (right to buy) | +91,406 | 91,406 | ||
| 2021-01-13 | Stultz Katherine V CHIEF OPERATING OFFICER | Grant or award · Stock Option (right to buy) | +99,753 | 99,753 | ||
| 2021-01-13 | JIMENEZ JOSEPH Director | Grant or award · Stock Option (right to buy) | +49,876 | 49,876 | ||
| 2021-01-13 | KARSEN PERRY A Director | Grant or award · Stock Option (right to buy) | +74,794 | 74,794 | ||
| 2021-01-13 | Lehrer-Graiwer Joshua PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +374,013 | 374,013 |
Page 11 of 11 · 217 trades